Market capitalization | DKK58.92b |
Enterprise Value | DKK50.38b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 136.91 |
P/S ratio (TTM) P/S ratio | 160.12 |
P/B ratio (TTM) P/B ratio | 6.27 |
Revenue growth (TTM) Revenue growth | 301.39% |
Revenue (TTM) Revenue | DKK367.97m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
9 Analysts have issued a Zealand Pharma forecast:
9 Analysts have issued a Zealand Pharma forecast:
Jun '24 |
+/-
%
|
||
Revenue | 368 368 |
301%
301%
|
|
Gross Profit | 335 335 |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -721 -721 |
1%
1%
|
Net Profit | -712 -712 |
28%
28%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.
Head office | Denmark |
CEO | Adam Steensberg |
Employees | 253 |
Founded | 1997 |
Website | www.zealandpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.